Matched cohort studies revealed infrequent adverse events (AEs) with either treatment, but the number needed to harm for any AE was more than three times higher with colchicine vs NSAIDs. The ...

Patients with gout are commonly prescribed colchicine prophylaxis, despite already taking medications that could potentially interact. Patients with gout are commonly prescribed colchicine prophylaxis ...

In a phase 2 trial, firsekibart — an IL-1 beta antibody — outperforms colchicine in preventing acute gout flares over 12 ...

Gout is the most common form of inflammatory arthritis, with a worldwide prevalence of approximately 4%. The accumulation of ...

Due to a policy decision in 2010 by the U.S. Food and Drug Administration (FDA), the price of a prescription for the therapeutic gout drug colchicine increased nearly 16-fold from $11.25 in 2009 to ...

• Colchicine: While colchicine has successfully treated both acute and chronic gout for ages, clinicians must be judicious about dosing. No one should be dosing patients with acute gout “to the onset ...

Additionally, colchicine use was higher in the febuxostat than the allopurinol group in FAST. “To what extent the results of FAST are generalisable to patients with gout who have not previously been ...

Please provide your email address to receive an email when new articles are posted on . The 2010 increase in colchicine prices was immediately followed by a decrease in the drug’s use for gout.

Due to a policy decision in 2010 by the U.S. Food and Drug Administration (FDA), the price of a prescription for the therapeutic gout drug colchicine increased nearly 16-fold from $11.25 in 2009 to ...

The comparative efficacy of these therapies has been extended to patients with stage 3 chronic kidney disease, a common comorbidity in gout. Allopurinol and febuxostat are similarly effective in ...